

Special Issue

New Advances in Treatment of Sepsis

Message from the Guest Editor

Sepsis is now defined as an organ dysfunction caused by an overwhelming and life-threatening host response to infection. Excessive inflammatory response in sepsis subsequently leads to multiple organ dysfunction syndrome due to vascular endothelial dysfunction, coagulation disorders, alterations in cell function, and dysregulated cardiovascular responses. Despite the progress made in medical management over the past few decades, sepsis remains an important global health problem, with approximately 11 million sepsis-related deaths reported in 2017. Although various strategies to control sepsis-induced inflammation and organ dysfunction have been evaluated over the past several decades, there is still no proven therapeutic intervention benefitting survival. Therefore, updating knowledge on the pathophysiology of sepsis is a vitally important issue to construct a novel therapeutic strategy of sepsis. In this Special Issue of the *Journal of Personalized Medicine*, we will discuss the etiology, pathophysiology, clinical manifestations, diagnostic, and optimal management to treat critically ill patients with sepsis.

Guest Editor

Dr. Yutaka Umemura

Division of Trauma and Surgical Critical Care, Osaka General Medical Center, Osaka, Japan

Deadline for manuscript submissions

closed (27 May 2022)



Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/84402

*Journal of Personalized
Medicine*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/journal/

[jpm](https://mdpi.com/journal/)



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on “omics”-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 25 days after submission; acceptance to publication is undertaken in 5.8 days (median values for papers published in this journal in the second half of 2025).